COMPARATIVE ANALYSIS OF LABORATORY PARAMETERS OF HEMATOPOIESIS AND HEMOSTATIC STATUS IN PATIENTS WITH POLYCYTHEMIA AND ESSENTIAL THROMBOCYTHEMIA.
Abstract
Chronic myeloproliferative diseases (CMP) are a group of clonal hematological diseases that occur at the hematopoietic stem cell level and are characterized by the proliferation of one or more myelopoiesis cell lines in the bone marrow with signs of preserved terminal differentiation. The causes of chronic myeloproliferative pathologies are not reliably known. Clinicalmanifestations of this group of pathologies are usually not specific and require careful differential diagnosis with other diseases
References
Melikyan A.L., Turkina A.G., Abdulkadyrov K.M., Zaritskiy A.Yu., Afanasiev B.V., Shuvaev V.A., et al. Clinical recommendations for the diagnosis and therapy of Ph-negative myeloproliferative diseases (true polycythemia, essential thrombocythemia, primary myelofibrosis). Hematology and transfusiology. Russian Journal (Gematologiya i transfusiologiya). 2014; 59(4): 31–56. (in Russian)
Vardiman J.W., Thiele J., Arber D.A., Brunning R.D., Borow-itz M.J., Porwit A. et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neo-plasms and acute leukemia: rationale and important changes. Blood. 2009; 114(5): 937–951.
Melikyan A.L., Suborceva I.N. Biology of myeloprolif-erative diseases. Clinical oncohematology. Russian Journal (Klinicheskaya onkogematologiya). 2016; 9(3): 314–25. doi: 10.1182/blood-2009-03-209262. (in Russian)
Xalilov, Hikmatulla, et al. "TELEMEDITSINANING PROFILAKTIK DAVOLANISHDA AHAMIYATI." Евразийский журнал академических исследований 4.4 Part 2 (2024): 66-70.
Campbell P.J., Scott L.M., Buck G., Wheatley K., East C.L., Marsden J.T., et al. Definition of subtypes of essen-tial thrombocythaemia and relation to polycythaemia vera based on JAK2V617F mutation status: a prospective study. Lancet. 2005; 366(9501): 1945–53. doi.org/10.1016/S0140-6736(05)67785-9.
Treglazova S.A., Abdullaev A.O., Makarik T.V., Subortseva I.N., Melikyan A.L., Sudarikov A.B. Study of mutations of JAK2V617F, MPL W515L/K and 9 exon of the CALR gene in patients with essential thrombocythemia. Hematology and transfusiology. Russian Journal (Gematologiya i transfusi-ologiya). 2016; 61(1, Suppl. 1): 74. (in Russian)
Dilshodovich, Khalilov Hikmatulla, Kayimov Mirzohid Normurotovich, and Esanov Alisher Akromovich. "RELATIONSHIP BETWEEN THYROID DISEASE AND TYPE 2 DIABETES." (2023).
Ding J., Komatsu H., Wakita A., Kato-Uranishi M., Ito M., Satoh A., et al. Familial essential thrombocythemia associ-ated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombo-poietin. Blood. 2004; 103(11): 4198–200. doi: https://doi. org/10.1182/blood-2003-10-3471
Nangalia J., Massie C.E., Baxter E.J., Nice F.L., Gundem G., Wedge D.C., et.al. Somatic CALR Mutations in Myeloprolif-erative Neoplasms with Nonmutated JAK2. N. Engl. J. Med. 2013;369(25):2391–405. doi: 10.1056/NEJMoa1312542
Klampfl T., Gisslinger H., Harutyunyan A.S., Nivarthi H., Rumi E., Milosevic J.D., et al. Somatic mutations of calretic-ulin in myeloproliferative neoplasms. N. Engl. J. Med 2013; 369(25): 2379–90. doi: 10.1056/NEJMoa1311347
Passamonti F., Rumi E., Pietra D., Elena C., Boveri E., Arcai-ni L., et al. A prospective study of 338 patients with polycy-themia vera: The impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia. 2010; 24(9): 1574–9. doi: 10.1038/leu.2010.148.
Varricchio L., Mancini A., Migliaccio A.R. Pathological in-teractions between hematopoietic stem cells and their niche revealed by mouse models of primary myelofibrosis. Expert Rev. Hematol. 2009; 2(3): 315–34. doi: 10.1586/ehm.09.17
Xalilov, X. D., N. K. SHadmanova, and M. N. Qayumov. "Gipertireorizmni exsperemental modellashtirish." (2023).
Cho S.Y., Xu M., Roboz J., Lu M., Mascarenhas J., Hoffman R. The Effect of CXCL12 Processing on CD34+ Cell Migra-tion in Myeloproliferative Neoplasms. Cancer Res. 2010; 70(8): 3402–10. doi: 10.1158/0008-5472.CAN-09-3977.
Vannucchi A.M., Barbui T., Cervantes F., Harrison C., Kil-adjian J.J., Kroger N., et al.; ESMO Guidelines Committee. Philadelphia chromosome-negative chronic myeloprolifera-tive neoplasms: ESMO clinical practice guidelines for diag-nosis, treatment and follow-up. Ann. Oncol. 2015; 26(Suppl. 5): v85–99. doi: 10.1093/annonc/mdv203.
